AnaptysBio to Drop Eczema Drug Candidate
AnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares Fall
The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, often referred to as eczema.
AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
H.C. Wainwright downgraded AnaptysBio (ANAB) to Neutral from Buy with a price target of $19, down from $52, after the company announced topline ...
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...
Anaptys Bio (NASDAQ:ANAB) stock plunged 33% Wednesday after the company said it was scrapping further development of its drug ...
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...
BTIG downgraded AnaptysBio (ANAB) to Neutral from Buy without a price target The company’s topline data from the Phase 2b trial of ANB032 in atopic dermatitis are expected later in December and ...
Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study p ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback